Molecular aspects of the antiviral response against hepatitis C virus implicated in vaccines development

被引:1
作者
Soledad Llanes, Maria [1 ]
Soledad Palacios, Natalia [1 ]
Piccione, Magali [1 ]
Guillermina Ruiz, Maria [1 ]
Layana, Carla [1 ,2 ]
机构
[1] Univ Nacl Noroeste Buenos Aires, Dept Ciencias Basicas & Expt, Buenos Aires, DF, Argentina
[2] Univ Nacl La Plata, Fac Ciencias Exactas, Ctr Reg Estudios Genom, Buenos Aires, DF, Argentina
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2015年 / 33卷 / 04期
关键词
Hepatitis C; Vaccines; Treatment; I CLINICAL-TRIAL; CANDIDATE VACCINE; PLUS RIBAVIRIN; NEUTRALIZING ANTIBODIES; THERAPEUTIC VACCINATION; IMMUNE-RESPONSES; PROTEIN; PHASE; INFECTION; PARTICLES;
D O I
10.1016/j.eimc.2013.12.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Hepatitis C is a contagious liver disease caused by hepacivirus of the Flaviviridae family. It has a RNA genome, a unique highly variable molecule. It encodes ten proteins which are necessary to infect cells and multiply. Replication occurs only in hepatocytes. Because of its wide genomic variability and the absence of symptoms, it is difficult to make an early diagnosis and successful treatment. In this review we analyze the molecular mechanism by which the virus infects the hepatocytes and causes the disease. We focused the analysis on different therapies, with the possibility of improving treatment with the use of new specific vaccines. We highlight the use of new therapies based on nucleic acids, mainly DNA vectors. In the near future, once this treatment is adequately evaluated in clinical trials, and the costs are calculated, it could be a very beneficial alternative to conventional methods. (C) 2013 Elsevier Espana, S.L.U. and Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 66 条
  • [1] Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
    Alvarez-Lajonchere, L.
    Shoukry, N. H.
    Gra, B.
    Amador-Canizares, Y.
    Helle, F.
    Bedard, N.
    Guerra, I.
    Drouin, C.
    Dubuisson, J.
    Gonzalez-Horta, E. E.
    Martinez, G.
    Marante, J.
    Cinza, Z.
    Castellanos, M.
    Duenas-Carrera, S.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2009, 16 (03) : 156 - 167
  • [2] Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus
    Arribillaga, L
    de Cerio, ALD
    Sarobe, P
    Casares, N
    Gorraiz, M
    Vales, A
    Bruna-Romero, O
    Borrás-Cuesta, F
    Paranhos-Baccala, G
    Prieto, J
    Ruiz, J
    Lasarte, JJ
    [J]. VACCINE, 2002, 21 (3-4) : 202 - 210
  • [3] Novel Therapeutic Approaches for Hepatitis C
    Au, J. S.
    Pockros, P. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (01) : 78 - 88
  • [4] Uptake and presentation of hepatitis C virus-like particles by human dendritic cells
    Barth, H
    Ulsenheimer, A
    Pape, GR
    Diepolder, HM
    Hoffmann, M
    Neumann-Haefelin, C
    Thimme, R
    Henneke, P
    Klein, R
    Paranhos-Baccalà, G
    Depla, E
    Liang, TJ
    Blum, HE
    Baumert, TF
    [J]. BLOOD, 2005, 105 (09) : 3605 - 3614
  • [5] Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate
    Baumert, TF
    Vergalla, J
    Satoi, J
    Thomson, M
    Lechmann, M
    Herion, D
    Greenberg, HB
    Ito, S
    Liang, TJ
    [J]. GASTROENTEROLOGY, 1999, 117 (06) : 1397 - 1407
  • [6] Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKε
    Breiman, A
    Grandvaux, N
    Lin, RT
    Ottone, C
    Akira, S
    Yoneyama, M
    Fujita, T
    Hiscott, J
    Meurs, EF
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (07) : 3969 - 3978
  • [7] New agents for the treatment of Hepatitis C
    Buti, Maria
    Horns, Maria
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2012, 30 (03): : 147 - 150
  • [8] Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy
    Cannon, Nathan A.
    Donlin, Maureen J.
    Fan, Xiaofeng
    Aurora, Rajeev
    Tavis, John E.
    [J]. PLOS ONE, 2008, 3 (05): : 1 - 12
  • [9] A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques
    Capone, S
    Meola, A
    Ercole, BB
    Vitelli, A
    Pezzanera, M
    Ruggeri, L
    Davies, ME
    Tafi, R
    Santini, C
    Luzzago, A
    Fu, TM
    Bett, A
    Colloca, S
    Cortese, R
    Nicosia, A
    Folgori, A
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (04) : 1688 - 1699
  • [10] ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME
    CHOO, QL
    KUO, G
    WEINER, AJ
    OVERBY, LR
    BRADLEY, DW
    HOUGHTON, M
    [J]. SCIENCE, 1989, 244 (4902) : 359 - 362